Clinical trials: Movement Disorder
Huntington Disease
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
- Trial name
- NCT04514367
- Testing
- ANX005
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Annexon, Inc.
Malocclusion
Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners
The purpose of this study is to examine the amount of tooth movement achieved over time between subjects undergoing aligner treatment using a pulsation device known as AcceleDent® Aura with those not using the device.
- Trial name
- NCT01962012
- Testing
- AcceleDent Aura
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- OrthoAccel Technologies Inc.
Parkinson's Disease
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
- Trial name
- NCT00199381
- Testing
- Istradefylline
- Where
- United States
- Volunteers
- 504 people
- Sponsor
- Kyowa Kirin, Inc.
Healthy Volunteers
A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects
To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant.
- Trial name
- NCT03954600
- Testing
- NPT520-34 (125 mg)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Neuropore Therapies Inc.
Parkinson Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT06553027
- Testing
- CVN424 75 mg, CVN424 150 mg
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Cerevance
Attention Deficit Disorder With Hyperactivity
Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients
The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00664703
- Testing
- Lobeline sulfate, Methylphenidate HCl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yaupon Therapeutics
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Parkinson Disease
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
- Trial name
- NCT03733561
- Testing
- LY03003, Neupro 4Mg/24Hr Transdermal Patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Parkinson's Disease
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
- Trial name
- NCT00203177
- Testing
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 254 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Dystonia, Dystonic Disorder
Meditoxin® Treatment in Patients With Cervical Dystonia
To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)
- Trial name
- NCT03232320
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Medy-Tox
Parkinson Disease
Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.
The objective of this study is the longitudinal prospective clinical evaluation in patients with motor predominant PD; it will assess the individual disease progression (change) of the clinical and imaging parameters measured at…
- Trial name
- PARK001 (NCT03960242)
- Where
- 2 sites in France
- Volunteers
- 3 people
- Sponsor
- BrainEver
Tourette Syndrome
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a…
- Trial name
- NCT03325010
- Testing
- Valbenazine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 127 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
- Trial name
- NCT02157714
- Testing
- PRX002
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Prothena Biosciences Limited
Parkinson Disease
An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
The clinical trial aims to evaluate the safety and effectiveness of bilateral subthalamic nucleus (STN) and Globus Pallidus internus (GPi) deep brain stimulation (DBS) with the AlphaDBS IPG System when programmed in adaptive…
- Trial name
- ADVENT (NCT05262348)
- Testing
- adaptive DBS delivered through AlphaDBS IPG System, conventional DBS delivered through AlphaDBS IPG System
- Sponsor
- Newronika
Essential Tremor
Adaptive Portable Essential Tremor Monitor
The purpose of this study is to evaluate the utility of a portable motion sensor-based system designed to monitor essential tremor (ET) to better prescribe therapy to minimize symptoms and expand care for ET patients.
- Trial name
- NCT01602042
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.
- Trial name
- NCT01603069
- Testing
- AZD3241 300 mg BID, AZD3241 600 mg BID
- Where
- 13 sites in United States
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Parkinson Disease
Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease
To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by determination of the prevalence of depression in PD…
- Trial name
- NCT00752388
- Where
- 278 sites in Germany
- Volunteers
- 1,588 people
- Sponsor
- Boehringer Ingelheim
Parkinson´s Disease
Rostock International Parkinson's Disease Study (ROPAD)
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the…
- Trial name
- ROPAD (NCT03866603)
- Where
- 110 sites in United States, Albania and 13 more
- Volunteers
- 20,112 people
- Sponsor
- CENTOGENE GmbH Rostock